CAR-T(CAR-T)细胞疗法在非肿瘤性疾病中的应用
Chimeric antigen receptor T (CAR-T) cell therapy in non-oncological diseases.
CAR-T(CAR-T)细胞在血液系统恶性肿瘤中的应用推动了这种免疫治疗形式的显著进展。
CELL INTELLIGENCE · 肿瘤细胞治疗研究
肿瘤细胞治疗研究
英文原题:The adenylyl cyclase activator forskolin pretreatment reprograms CAR-T cells toward a stem-like state to enhance solid tumor therapy.
The adenylyl cyclase activator forskolin pretreatment reprograms CAR-T cells toward a stem-like state to enhance solid tumor therapy.
分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。
腺苷酸环化酶激活剂毛喉素预处理可将CAR-T 细胞重编程为干细胞样状态,从而增强实体瘤治疗。嵌合抗原受体(CAR)T细胞疗法在血液系统恶性肿瘤中取得显著成功,但其对实体瘤的疗效仍有限,主要原因是T细胞耗竭。增强T细胞的记忆样特性和干性已成为克服这一障碍的有前景策略。本研究显示,干细胞诱导化合物毛喉素可将CAR-T 细胞重编程为干性升高的记忆样状态。毛喉素预处理的CAR-T 细胞富集记忆表型、耗竭程度降低,并在体外和体内表现出增强的抗肿瘤活性。转录组分析进一步发现毛喉素处理后CXCR4和BCL6上调;功能性阻断这些通路会削弱毛喉素的有益效应,凸显其在增强CAR-T 细胞干性中的关键作用。本研究提出将干细胞重编程药物纳入CAR-T 策略的新方法,并提供潜在治疗靶点,以提高CAR-T 细胞疗法对实体瘤的疗效。
Chimeric antigen receptor (CAR)-T cell therapy has achieved remarkable success in hematological malignancies; however, its efficacy against solid tumors remains limited, primarily due to T cell exhaustion. Enhancing memory-like properties and stemness of T cells has emerged as a promising strategy to overcome this barrier. In this study, we demonstrate that Forskolin, a stem cell-inducing compound, reprograms CAR-T cells toward a memory-like state characterized by elevated stemness.
Forskolin-pretreated CAR-T cells exhibited enriched memory phenotypes, reduced exhaustion, and enhanced anti-tumor activity both in vitro and in vivo. Transcriptomic profiling further revealed upregulation of CXCR4 and BCL6 following Forskolin treatment, and functional blockade of these pathways attenuated the beneficial effects of Forskolin, underscoring their critical roles in reinforcing CAR-T cell stemness.
Our findings highlight a novel strategy that integrates stem cell-reprogramming agents to enhance CAR-T cell stemness and provide potential therapeutic targets to improve the efficacy of CAR-T cell therapy against solid tumors.
MEMBER ACCOUNT
登录成功会直接打开下一页。